NCT01343082

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

A Long-term Open-label Study of DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension -Phase 3-

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 148 (actual)
• Sponsor: Santen Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: —

Summary

Safety and IOP (intraocular pressure) lowering effect of DE-111 ophthalmic solution will be evaluated in open-angle glaucoma or ocular hypertension patients, in an open-label, multicenter study.

Conditions

• Open Angle Glaucoma or Ocular Hypertension

Interventions

Type	Name	Description
DRUG	DE-111 ophthalmic solution

Timeline

• Start date: 2011-05-01
• Primary completion: 2013-03-01
• First posted: 2011-04-27
• Last updated: 2015-06-15
• Results posted: 2015-05-14

Locations

1 site across 1 country: Japan